Shots:

• Innocoll will make near-term payments to DURECT of $6M, including $4M license fee and a $2M payment upon 1st commercial sale, and an additional ~$130M in commercial, regulatory and intellectual property milestone payments as well as royalties on net product sales in the US
• Innocoll received the exclusive right to develop & commercialize Posimir in the US and the right to conduct additional development activities to expand the approved indications for Posimir
• The company’s contract manufacturing supply agreement for Posimir is also assigned to Innocoll while DURECT retains all commercial rights to Posimir throughout the RoW. Posimir’s launch is expected in the Q2’2022, subject to commercial supply timelines

Ref: Durect | Image: Durect